Druggability Technologies (DRGT) has entered into a multi-year collaboration deal with Bayer HealthCare that will deploy DRGT's proprietary Super-API platform to support Bayer HealthCare's formulation efforts directed at enhancing compound solubility and bioavailability.
The deal calls for the application of DRGT's platform from early compound screening to clinical formulation of candidate drugs.
It is expected that the platform will be applied across a range of compounds where such are burdened by low solubility and poor bioavailability.
DRGT's proprietary Super-API platform is designed to speed up the drug selection and development of novel drug candidates.
The deal will include support and funding the Super-API development platform application to Bayer compounds and is also expected that DRGT will contribute in the production of Bayer HealthCare Super-API constructed compounds during clinical development and in manufacture for sale.
DRGT CEO Gabor Heltovics said, "We believe that the application of our Super-API technology to the discovery and development portfolio of Bayer will help unlock the full potential of many drug candidates and can deliver clinically important benefits to patients."
